keyword
MENU ▼
Read by QxMD icon Read
search

bisphosphonates pain

keyword
https://www.readbyqxmd.com/read/29242791/managing-recurrence-in-intraarticular-melorheostosis-involving-the-knee-joint-a-case-report
#1
Bobby John, Anirudh Sharma, Ritesh A Pandey
Introduction: Melorheostosis is a rare benign sclerosing dysplasia affecting bone, which causes significant morbidity in the form of pain and restriction of joint movement. Treatment options are varied, and recurrence is common after surgical treatment. Choosing the most appropriate treatment option in the management of a recurrent case is challenging, with very little supporting evidence in literature owing to the rarity of the disease. We hereby present a case of recurrent melorheostosis involving the knee; discuss treatment options and the rationale of our treatment...
September 2017: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/29237448/surgical-outcome-of-atypical-subtrochanteric-and-femoral-fracture-related-to-bisphosphonates-use-in-osteoporotic-patients-with-or-without-teriparatide-treatment
#2
Wen-Ling Yeh, Chun-Yi Su, Chia-Wei Chang, Chien-Hao Chen, Tsai-Sheng Fu, Lih-Huei Chen, Tung-Yi Lin
BACKGROUND: Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing. Limited data have revealed that teriparatide treatment may reverse the effect of bisphosphonates and be effective in bone healing. METHODS: We reviewed patients with atypical subtrochanteric and femoral fracture related to bisphosphonates use between January 2008 and December 2014...
December 13, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29236045/clodronate-as-a-therapeutic-strategy-against-osteoarthritis
#3
Maria Teresa Valenti, Monica Mottes, Alessandro Biotti, Massimiliano Perduca, Arianna Pisani, Michele Bovi, Michela Deiana, Samuele Cheri, Luca Dalle Carbonare
Osteoarthritis (OA), the most prevalent musculoskeletal pathology, is mainly characterized by the progressive degradation of articular cartilage due to an imbalance between anabolic and catabolic processes. Consequently, OA has been associated with defects in the chondrocitic differentiation of progenitor stem cells (PSCs). In addition, SOX9 is the transcription factor responsible for PSCs chondrogenic commitment. To evaluate the effects of the non-amino bisphosphonate clodronate in OA patients we investigated SOX9 gene expression in circulating progenitor cells (CPCs) and in an in vitro OA model...
December 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29230158/significant-improvement-of-clinical-symptoms-bone-lesions-and-bone-turnover-after-long-term-zoledronic-acid-treatment-in-patients-with-a-severe-form-of-camurati-engelmann-disease
#4
Giampiero I Baroncelli, Elena Ferretti, Cecilia M Pini, Benedetta Toschi, Rita Consolini, Silvano Bertelloni
Camurati-Engelmann disease (CED) is an ultrarare autosomal dominant bone dysplasia. Cortical thickening of the diaphyses of the long bones with narrowing of the medullary cavity are associated with bone pain, waddling gait, muscular weakness, easy fatigability, and a marfanoid body habitus. There is no specific treatment for CED. Nonsteroidal anti-inflammatory drugs or glucocorticoids are ineffective in improving bone lesions. A family with a mild to severe form of CED is described. Two patients received long-term bisphosphonate treatment: the 19-year-old female proband was treated with zoledronic acid for 2...
November 2017: Molecular Syndromology
https://www.readbyqxmd.com/read/29222056/are-bisphosphonates-efficacious-in-knee-osteoarthritis-a-meta-analysis-of-randomized-controlled-trials
#5
Elizaveta E Vaysbrot, Mikala C Osani, Mia-Cara Musetti, Timothy E McAlindon, Raveendhara R Bannuru
OBJECTIVE: To clarify the effects of bisphosphonates in knee osteoarthritis (OA) using an up-to-date meta-analysis of randomized controlled trials (RCTs). DESIGN: The protocol is registered in PROSPERO (CRD42017073449). We searched MEDLINE, EMBASE, Google Scholar, Web of Science, and Cochrane Database from inception until August 2017. We included only RCTs comparing any bisphosphonates vs. placebo in knee OA patients and reporting validated pain and function scales, radiographic progression, and adverse events outcomes...
December 5, 2017: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/29221983/medication-related-osteonecrosis-of-the-jaws-associated-with-targeted-therapy-as-monotherapy-and-in-combination-with-antiresorptives-a-report-of-7-cases-from-the-copenhagen-cohort
#6
Hoda Abel Mahedi Mohamed, Charlotte Emilie Nor Nielsen, Morten Schiodt
OBJECTIVE: The aim of this study was to report cases of medication-related osteonecrosis of the jaws (MRONJ) associated with targeted therapy (TT) with or without concomitant antiresorptive treatment, among the Copenhagen ONJ cohort, which includes all consecutive cases of MRONJ seen in Copenhagen. STUDY DESIGN: We retrospectively studied the treatment of 204 consecutive patients with MRONJ, seen between January 2010 and May 2016, to identify those associated with TT...
November 6, 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29207391/tooth-extraction-locally-stimulates-proliferation-of-multiple-myeloma-in-a-patient-with-mandibular-localizations
#7
Jean-Daniel Kün-Darbois, Léonie Quenel, Smaïl Badja, Daniel Chappard
OBJECTIVES: Multiple myeloma (MM) is characterized by the occurrence of osteolytic lesions. MM treatment usually involves antiresorptive drugs (mainly bisphosphonates). CASE REPORT: A patient with an MM presented osteolytic lesions of the mandible. Extraction of teeth 45 and 46 was performed 5 years after the diagnosis of periodontitis. Four months later, osteonecrosis of the jaw (ONJ) was diagnosed at the extraction site. X-ray showed an extension of osteolytic lesions on the right side, close to the extraction site, without modification of the lesions on the left side...
December 6, 2017: Acta Haematologica
https://www.readbyqxmd.com/read/29204337/effects-on-bone-resorption-markers-of-continuing-pamidronate-or-switching-to-zoledronic-acid-in-patients-with-high-risk-bone-metastases-from-breast-cancer
#8
J F Hilton, M Clemons, G Pond, H Zhao, S Mazzarello, L Vandermeer, C L Addison
Background: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone resorption, such as Bone-Specific Alkaline Phosphatase (BSAP), bone sialoprotein (BSP), and N-terminal telopeptide (NTX) correlated with subsequent SRE risk. Methods: Breast cancer patients who remained at high risk of SREs despite at least 3 months of q...
March 2018: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29192692/detecting-the-earliest-radiological-signs-of-bisphosphonate-related-osteonecrosis
#9
H Devlin, J Greenwall-Cohen, J Benton, T L Goodwin, A Littlewood, K Horner
Introduction Oral bisphosphonates are the most commonly prescribed anti-resorptive drugs used in the treatment of osteoporosis, but osteonecrosis of the jaw is a serious complication. The early diagnosis of this destructive side effect is crucial in preventing excessive bone loss, pain and infection.Objective To aid dental practitioners in the early identification of bisphosphonate-related osteonecrosis of the jaw.Method A scoping review was carried out.Data sources We searched MEDLINE via OVID, EMBASE via OVID, Dentistry and Oral Sciences Source (DOSS), Proquest Dissertation and Theses Search, to identify references that described clinical and radiological findings in medication-related osteonecrosis of the jaw (MRONJ)...
November 17, 2017: British Dental Journal
https://www.readbyqxmd.com/read/29192423/bisphosphonates-for-paget-s-disease-of-bone-in-adults
#10
REVIEW
Luis Corral-Gudino, Adrian Jh Tan, Javier Del Pino-Montes, Stuart H Ralston
BACKGROUND: Bisphosphonates are considered to be the treatment of choice for people with Paget's disease of bone. However, the effects of bisphosphonates on patient-centred outcomes have not been extensively studied. There are insufficient data to determine whether reducing and maintaining biochemical markers of bone turnover to within the normal range improves quality of life and reduces the risk of complications. OBJECTIVES: To assess the benefits and harms of bisphosphonates for adult patients with Paget's disease of bone...
December 1, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29175022/biology-and-treatment-of-myeloma-related-bone-disease
#11
Evangelos Terpos, Dimitrios Christoulas, Maria Gavriatopoulou
Myeloma bone disease (MBD) is the most common complication of multiple myeloma (MM), resulting in skeleton-related events (SREs) such as severe bone pain, pathologic fractures, vertebral collapse, hypercalcemia, and spinal cord compression that cause significant morbidity and mortality. It is due to an increased activity of osteoclasts coupled to the suppressed bone formation by osteoblasts. Novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition have recently been described, including the receptor activator of nuclear factor-kB ligand/osteoprotegerin pathway, activin-A and the wingless-type signaling inhibitors, dickkopf-1 (DKK-1) and sclerostin...
November 23, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29172394/subchondral-insufficiency-fracture-in-the-lateral-compartment-of-the-knee-in-a-64-year-old-marathon-runner
#12
Vincent Vg An, Mathias van den Broek, Sam Oussedik
A 64-year-old marathon runner presented to our clinic with a history of worsening pain in her left knee. Following magnetic resonance imaging, the diagnosis of subchondral insufficiency fracture of the knee (SIFK) was made. A course of conservative management via bisphosphonates was initiated. The patient successfully recovered and returned to full athletic function, having recently returned to competitive marathon running. This article aims to present this unusual case of lateral compartment SIFK and summarise the literature on this uncommon condition...
December 1, 2017: Knee Surgery & related Research
https://www.readbyqxmd.com/read/29146440/clodronate-a-vesicular-atp-release-blocker
#13
REVIEW
Yoshinori Moriyama, Masatoshi Nomura
Clodronate is a first-generation bisphosphonate used worldwide for antiresorptive therapy for osteoporosis. Although clodronate is analgesic in nature, its mechanism and efficacy were unknown for some time. Recently, clodronate was identified as a selective and potent inhibitor for vesicular nucleotide transporter (VNUT), a transporter responsible for vesicular storage of ATP. Clodronate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain following blockade of purinergic chemical transmission...
November 13, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29143901/combined-vertebral-augmentation-and-radiofrequency-ablation-in-the-management-of-spinal-metastases-an-update
#14
REVIEW
Ning Mao Kam, Julian Maingard, Hong Kuan Kok, Dinesh Ranatunga, Duncan Brooks, William C Torreggiani, Peter L Munk, Michael J Lee, Ronil V Chandra, Hamed Asadi
Spinal metastases are the most commonly encountered tumour of the spine, occurring in up to 40% of patients with cancer. Each year, approximately 5% of cancer patients will develop spinal metastases. This number is expected to increase as the life expectancy of cancer patients increases. Patients with spinal metastases experience severe and frequently debilitating pain, which often decreases their remaining quality of life. With a median survival of less than 1 year, the goals of treatment in spinal metastases are reducing pain, improving or maintaining level of function and providing mechanical stability...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29127574/biologic-treatment-for-chronic-recurrent-multifocal-osteomyelitis-report-of-four-cases-and-review-of-the-literature
#15
REVIEW
Elena Tronconi, Angela Miniaci, Michelangelo Baldazzi, Laura Greco, Andrea Pession
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare non-infectious inflammatory disorder with unpredictable clinical course, characterized by acute exacerbations and spontaneous remissions. There are no randomized-controlled trials about treatment options. Non-steroidal anti-inflammatory drugs (NSAID) are the first-line treatment option; glucocorticoids seem to be effective; positive outcomes have been obtained with bisphosphonates. In the last few years successful use of biologic agents like anti-TNF agents has been reported...
November 11, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29125079/-relapse-of-chronic-inflammatory-demyelinating-polyneuropathy-following-treatment-with-zoledronic-acid
#16
M Loef, E C T Geijteman, K J Beelen, M Bornebroek, D H Schweitzer
BACKGROUND: Zoledronic acid is a nitrogen-containing bisphosphonate that is frequently used in the treatment of osteoporosis. Many patients experience a so-called acute-phase reaction during initial treatment; this is characterized by flu-like symptoms and fever. CASE DESCRIPTION: We describe a 61-year-old woman who suffered from chronic inflammatory demyelinating polyneuropathy (CIDP), and who was started on intravenous zoledronic acid treatment as adjuvant therapy for breast cancer...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29102332/conservative-treatment-of-children-with-chronic-diffuse-sclerosing-osteomyelitis-tendoperiostitis-of-the-mandible
#17
Marieke M van de Meent, Hamid Meshkini, Marta Fiocco, Miranda J M Wetselaar-Glas, Natasha M Appelman-Dijkstra, J P Richard van Merkesteyn
Chronic diffuse sclerosing osteomyelitis (DSO) of the mandible is a rare disease of unknown aetiology. It has been suggested that overuse of the masticatory muscles, tendoperiostitis (TP), is a contributing factor for DSO. Therefore, we tested this hypothesis by treating consecutive children with conservative therapy. All patients were treated with conservative therapy, comprising occlusal splint therapy, physiotherapy, and/or disease counselling. Pain intensity on a visual analogue scale (VAS) and pain frequency in number of days per 3 months were recorded before the start of treatment, and at 3, 6, and 12 months after treatment initiation...
October 3, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#18
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
October 18, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29098361/new-agents-in-the-treatment-of-myeloma-bone-disease
#19
REVIEW
Elizabeth S Ring, Michelle A Lawson, John A Snowden, Ingrid Jolley, Andrew D Chantry
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation. The bone phenotype is typified by focal osteolytic lesions leading to pathological fractures, hypercalcaemia and other catastrophic bone events such as spinal cord compression. This causes bone pain, impaired functional status, decreased quality of life and increased mortality. Early in the disease, malignant plasma cells occupy a niche environment that encompasses their interaction with other key cellular components of the bone marrow microenvironment...
November 2, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/29082518/bisphosphonates-and-other-bone-agents-for-breast-cancer
#20
REVIEW
Brent O'Carrigan, Matthew Hf Wong, Melina L Willson, Martin R Stockler, Nick Pavlakis, Annabel Goodwin
BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breast cancer (EBC); (ii) in women with advanced breast cancer without bone metastases (ABC); and (iii) in women with metastatic breast cancer and bone metastases (BCBM)...
October 30, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
75048
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"